Suppr超能文献

齐多夫定与去羟肌苷联合用药对血液及淋巴结的抗逆转录病毒作用。

Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes.

作者信息

Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J

机构信息

Department of Infectious Diseases, General Hospital, Toulon, France.

出版信息

AIDS. 1997 Jan;11(1):67-72. doi: 10.1097/00002030-199701000-00010.

Abstract

OBJECTIVE

To evaluate the antiretroviral effect of a combination of zidovudine (ZDV) and didanosine (ddl) on plasma, peripheral blood mononuclear cells (PBMC) and lymph nodes after 24 weeks.

METHODS

Eight patients naive of antiretroviral therapy were followed by monthly blood samples and two surgical lymph-node biopsies taken at baseline and after 24 weeks. CD4+ T cells were counted monthly by flow cytometry. Plasma HIV-1 RNA was measured monthly by polymerase chain reaction (PCR). Infectious cellular viraemia was measured monthly by a culture technique. Proviral DNA titres in PBMC were measured by endpoint dilution PCR at baseline and 24 weeks. Infectious HIV-1 and proviral DNA titres were measured in the lymph-node mononuclear cells (LNMC). The total HIV-1 RNA content of lymph nodes was measured by PCR. In some cases, phenotypic resistance to ZDV was measured, and codon 215 and 74 mutations in PBMC and LNMC were analysed.

RESULTS

A mean increase in CD4 cell count of 122 x 10(6)/l, a mean decrease in HIV-1 RNA of 1.47 log10 in plasma and a mean decrease in HIV-1 DNA titre of 0.63 log10 were found after 24 weeks of therapy. Nevertheless, there were no statistically significant changes in the mean infectious HIV-1 titre in PBMC and LNMC, in the HIV-1 DNA titre in LNMC or in the total lymph-node HIV-1 RNA burden at week 24. Phenotypic or genotypic markers of drug resistance were rarely found in PBMC at week 24, although they were detected in LNMC from some patients.

CONCLUSION

A discrepancy in the therapeutic effect can be observed between lymphoid organs and blood after 24 weeks of therapy with ZDV and ddl. This difference could be explained by the insufficient antiretroviral potency of this combination facing the significant viral burden present in lymph nodes. Development of drug resistance in this compartment prior to blood can be demonstrated in some cases, although other mechanisms remain to be investigated in future studies to explain this difference.

摘要

目的

评估齐多夫定(ZDV)与去羟肌苷(ddl)联合用药24周后对血浆、外周血单个核细胞(PBMC)及淋巴结的抗逆转录病毒效果。

方法

对8例未接受过抗逆转录病毒治疗的患者每月采集血样,并在基线期及24周后进行两次手术淋巴结活检。每月通过流式细胞术计数CD4 + T细胞。每月通过聚合酶链反应(PCR)检测血浆HIV-1 RNA。每月通过培养技术检测感染性细胞病毒血症。在基线期及24周时通过终点稀释PCR检测PBMC中的前病毒DNA滴度。在淋巴结单个核细胞(LNMC)中检测感染性HIV-1及前病毒DNA滴度。通过PCR检测淋巴结的总HIV-1 RNA含量。在某些情况下,检测对ZDV的表型耐药性,并分析PBMC及LNMC中密码子215和74的突变情况。

结果

治疗24周后,CD4细胞计数平均增加122×10⁶/L,血浆中HIV-1 RNA平均下降1.47 log₁₀,HIV-1 DNA滴度平均下降0.63 log₁₀。然而,在24周时,PBMC及LNMC中感染性HIV-1滴度的平均值、LNMC中HIV-1 DNA滴度或淋巴结总HIV-1 RNA负荷均无统计学上的显著变化。在24周时,PBMC中很少发现耐药的表型或基因型标志物,尽管在部分患者的LNMC中检测到了这些标志物。

结论

ZDV与ddl联合治疗24周后,可观察到淋巴器官与血液之间治疗效果存在差异。这种差异可能是由于该联合用药面对淋巴结中存在的大量病毒负荷时抗逆转录病毒效力不足所致。在某些情况下,可以证明在血液之前该区域出现了耐药性,尽管未来研究中仍需研究其他机制来解释这种差异。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验